

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroPort CardioFlow Medtech Corporation**

**微创心通医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2160)**

**(1) CHANGE OF DIRECTORS AND APPOINTMENT OF  
DEPUTY PRESIDENT;**

**AND**

**(2) CHANGE OF STOCK SHORT NAME**

**CHANGE OF DIRECTORS AND APPOINTMENT OF DEPUTY PRESIDENT**

**Resignation of Directors**

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, with effect from December 15, 2025, (i) each of Mr. Zhao Liang (趙亮) (“**Mr. Zhao**”) and Ms. Yan Luying (閆璐穎) (“**Ms. Yan**”) resigned as an executive Director as he/she would like to devote more time to his/her management commitment in the Group; and (ii) Mr. Zhang Junjie (張俊傑) (“**Mr. Zhang**”) resigned as a non-executive Director due to his personal work arrangements.

Each of Mr. Zhao, Ms. Yan and Mr. Zhang has confirmed to the Company that he/she does not have any disagreement with the Board and that there is no matter relating to his/her resignation that needs to be brought to the attention of the shareholders of the Company and/or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its appreciation to Mr. Zhao, Ms. Yan and Mr. Zhang for their valuable contributions to the Company during their tenure of office with the Board.

## **Appointment of Non-executive Director and Co-chairman**

The Board announces that, Dr. Brian Chang (“**Dr. Chang**”) has been appointed as a non-executive Director and the co-chairman of the Board with effect from December 15, 2025.

The biographical details of Dr. Chang are set out as follows:

Dr. Chang, aged 33, with a professional background as an engineer and physician-scientist, is the co-founder of several medical technology startups, where he has led early-stage research and development. Previously, Dr. Chang served as a postdoctoral and lecturer at Massachusetts Institute of Technology (“MIT”), where he oversaw interdisciplinary research teams and developed curriculum in cardiovascular physiology and medical technology. His academic research has focused on cardiac support devices and extracorporeal systems. He has authored 14 peer-reviewed publications and is a named inventor on multiple U.S. patents related to cardiovascular and extracorporeal technologies. Dr. Chang’s contributions have been recognized through numerous honors, including the Paul & Daisy Soros Fellowship, the Seidman Prize for Outstanding Thesis, and teaching awards from both Harvard Medical School and MIT. Since June 2025, Dr. Chang has served as the chief medical officer of MicroPort Scientific Corporation, the controlling shareholder of the Company, whose shares are listed on the Stock Exchange (stock code: 0853).

Dr. Chang obtained a bachelor’s degree and a master’s degree in mechanical engineering from Carnegie Mellon University in December 2013 and May 2014, respectively, graduating with University Honors and a minor in biomedical engineering. He obtained a Ph.D. in medical engineering and medical physics from the MIT in June 2018 and a M.D. from Harvard Medical School in May 2023, graduating magna cum laude. He completed his residency in Internal Medicine at Massachusetts General Hospital through the stanbury physician-scientist program in June 2025.

Dr. Chang has entered into a letter of appointment with the Company. The initial term of his appointment letter shall commence from the date of the appointment for a period of three years, and shall be subject to re-election as and when required under the articles of association of the Company, until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than three months’ prior notice in writing. He is not entitled to receive director’s fee from the Company. Dr. Chang’s remuneration will be subject to annual review by the remuneration committee of the Company and the Board from time to time with reference to the Company’s remuneration policy, the prevailing market level and his responsibilities and performance.

Dr. Chang shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.

Dr. Chang confirms that save as disclosed above, as of the date of this announcement, he does not (i) hold any other position in the Company or its subsidiaries nor any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (“**Listing Rules**”)) of the Company; and (iii) have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) of the Company or its associated corporations.

Save as disclosed above, the Board is not aware of any other information which is discloseable pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter relating to the appointment of Dr. Chang that needs to be brought to the attention of the shareholders of the Company.

### **Appointment of Executive Director and Deputy President**

The Board announces that, Mr. Philippe Wanstok (“**Mr. Wanstok**”) has been appointed as an executive Director and the deputy president of the Company with effect from December 15, 2025.

The biographical details of Mr. Wanstok are set out as follows:

Mr. Wanstok, aged 62, has been serving as the president of MicroPort Cardiac Rhythm Management Limited (微創心律管理有限公司) (“**CRM**”) since November 2024. He joined CRM in November 2017 as vice president of global sales and served as the senior vice president of global sales and marketing of CRM from September 2019 to November 2024. Mr. Wanstok has over 36 years of experience in the medical devices industry. Prior to joining CRM, from 1988 to 1995, Mr. Wanstok worked at Medtronic plc, a medical devices and medical technology company offering therapies for different health conditions (including cardiac rhythm management) whose shares are listed on the New York Stock Exchange (symbol: MDT). From 1995 to 1998, Mr. Wanstok worked at InControl Inc. (“**InControl**”), a company designing and developing medical devices aiming at treating Atrial Fibrillation as General Manager South Europe. InControl was acquired by Guidant Corporation in 1998. From 1998 to 2006, Mr. Wanstok worked at Guidant Corporation, a company principally engaged in the design and manufacturing of cardiovascular medical products with different roles including EMEA CRM marketing director and general manager of Spain. From 2006 to 2009, Mr. Wanstok worked at Boston Scientific Corporation, a medical devices company whose shares are listed on the New York Stock Exchange (symbol: BSX), where he was primarily responsible for establishing and launching marketing strategies for all international geographies. From 2009 to 2012, Mr. Wanstok returned to Medtronic plc as CRM International General Manager. From July 2012 to May 2017, he served as the chief commercial officer at CVRx Inc., a company engaged in the development and manufacturing of medical devices aiming at treating Heart Failure, whose shares are listed on the NASDAQ (symbol: CVRX).

Mr. Wanstok graduated from Paris University (Paris I-La Sorbonne) in France in June 1990, and completed a DESS in foreign trade, a diploma which is only accessible after obtaining a master's degree, in October 1989 with a major in economics.

Mr. Wanstok has entered into a service agreement with the Company. The initial term of his service agreement shall commence from the date of the appointment as an executive Director and continue for a period of three years, and shall be subject to re-election as and when required under the articles of association of the Company and the Listing Rules, until terminated in accordance with the terms and conditions of the service agreement or by either party giving to the other not less than 30 days' prior notice in writing. Pursuant to his service agreement, he is not entitled to receive director's fee from the Company. Mr. Wanstok's remuneration will be subject to annual review by the remuneration committee of the Company and the Board with reference to the Company's remuneration policy, the prevailing market level and his responsibilities and performance.

Mr. Wanstok shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.

As of the date of this announcement, Mr. Wanstok is interested in 18,523,140 shares of the Company (the "**Shares**") held by him within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Wanstok confirms that save as disclosed above, as of the date of this announcement, he does not (i) hold any other position in the Company or its subsidiaries nor any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under the Listing Rules) of the Company; and (iii) have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) of the Company or its associated corporations.

Save as disclosed above, the Board is not aware of any other information which is discloseable pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter relating to the appointment of Mr. Wanstok that needs to be brought to the attention of the shareholders of the Company.

### **Appointment of Non-Executive Director**

The Board announces that, Mr. Deng Aoyi (鄧奧弋) ("**Mr. Deng**") has been appointed as a non-executive Director with effect from December 15, 2025.

The biographical details of Mr. Deng are set out as follows:

Mr. Deng, aged 29, has amassed extensive experience in research, investment, and management across the healthcare sector. In November 2025, he joined CRM and was appointed as a director of CRM, where he was primarily responsible for participating in discussions on the group's major decision-making matters and providing strategic opinions and suggestions on the group's operation and management.

Currently serving at Yunfeng Capital (雲鋒基金), Mr. Deng leads and participates in investments and cross-border transactions across multiple sectors including biopharmaceuticals, cell therapies, medical devices and healthcare services. He has spearheaded or played a key role in the investment and post-investment management of nearly 20 portfolio companies to date.

Mr. Deng graduated from Peking University Health Science Center (北京大學醫學部) with a bachelor's degree in July 2020. In the same month, he obtained a dual bachelor's degree in economics from the National School of Development at Peking University (北京大學國家發展研究院). He obtained a master's degree in finance from Fudan University (復旦大學) in June 2022.

Mr. Deng has entered into a letter of appointment with the Company. The initial term of his appointment letter shall commence from the date of the appointment for a period of three years, and shall be subject to re-election as and when required under the articles of association of the Company, until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than three months' prior notice in writing. Pursuant to his letter of appointment, he is not entitled to receive director's fee from the Company. Mr. Deng's remuneration will be subject to annual review by the remuneration committee of the Company and the Board from time to time with reference to the Company's remuneration policy, the prevailing market level and his responsibilities and performance.

Mr. Deng shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.

Mr. Deng confirms that save as disclosed above, as of the date of this announcement, he does not (i) hold any other position in the Company or its subsidiaries nor any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under the Listing Rules) of the Company; and (iii) have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) of the Company or its associated corporations.

Save as disclosed above, the Board is not aware of any other information which is discloseable pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter relating to the appointment of Mr. Deng that needs to be brought to the attention of the shareholders of the Company.

The Board would like to welcome Dr. Chang, Mr. Wanstok and Mr. Deng for joining as members of the Board.

The Board will continue to uphold its commitment to diligent and responsible governance, focusing on strategic leadership, prudently evaluating and making decisions on matters critical to the Company's long-term development, and working closely with management to effectively execute the established strategy, all with the goal of maximizing value for shareholders.

## **CHANGE OF STOCK SHORT NAME**

The Board hereby announces that the stock short name for trading in the Shares on the Stock Exchange will be changed from "CARDIOFLOW-B" to "MP CARDIOFLOW-B" in English and from "心通醫療-B" to "微創心通-B" in Chinese with effect from 9:00 a.m. on December 22, 2025 in order to better reflect the controlling relationship between MicroPort Scientific Corporation, the Company's controlling shareholder, and the Company itself, while also aligning with the current consistent use of the trading name "MicroPort CardioFlow" and "微創心通" in the Company's sales and marketing activities and all daily operations. The English and Chinese names of the Company remain as "MicroPort CardioFlow Medtech Corporation" and "微創心通医疗科技有限公司" respectively, and the stock code of the Company on the Stock Exchange remains as "2160".

The change of stock short name of the Company will not affect any rights of the existing shareholders of the Company.

By Order of the Board  
**MicroPort CardioFlow Medtech Corporation**  
**Chen Guoming**  
*Chairman*

Shanghai, PRC, December 15, 2025

*As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Mr. Chen Guoming, Dr. Brian Chang, Mr. Deng Aoyi and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.*